Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer

NCT05116462 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

506

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Pemetrexed
DRUG: Carboplatin
DRUG: Paclitaxel
DRUG: Sintilimab
DRUG: Cisplatin
DRUG: Nab paclitaxel
DRUG: Placebo

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.